MASSMUTUAL TRUST CO FSB/ADV - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.

Quarter-by-quarter ownership
MASSMUTUAL TRUST CO FSB/ADV ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2023$3,223
+10.5%
45
-19.6%
0.00%
Q3 2023$2,917
+7.1%
56
+30.2%
0.00%
Q2 2023$2,723
+17.0%
430.0%0.00%
Q1 2023$2,328
+116300.0%
430.0%0.00%
Q4 2022$2
-99.9%
430.0%0.00%
Q3 2022$2,0000.0%43
+34.4%
0.00%
Q2 2022$2,0000.0%320.0%0.00%
Q1 2022$2,000
+100.0%
32
+166.7%
0.00%
Q4 2021$1,000120.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2022
NameSharesValueWeighting ↓
Sarissa Capital Management LP 675,000$26,203,0007.44%
EcoR1 Capital, LLC 244,950$9,509,0003.75%
Redmile Group, LLC 971,565$37,716,0003.60%
Ghost Tree Capital, LLC 120,000$4,658,0001.34%
SENZAR ASSET MANAGEMENT, LLC 144,624$5,614,304,0001.22%
GREAT POINT PARTNERS LLC 100,000$3,882,0001.11%
BB BIOTECH AG 700,000$27,174,0001.07%
Rhenman & Partners Asset Management AB 115,000$4,464,0000.79%
Lisanti Capital Growth, LLC 12,260$476,0000.72%
Rock Springs Capital Management LP 190,000$7,376,0000.55%
View complete list of INTRA CELLULAR THERAPIES INC shareholders